{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:26Z","timestamp":1793726006903,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Corvus Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03687-5","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:27:34Z","timestamp":1766500054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Soquelitinib inhibition of IL-2-inducible T cell kinase ameliorates lung damage in murine models of systemic sclerosis"],"prefix":"10.1186","volume":"27","author":[{"given":"Gon\u00e7alo","family":"Boleto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cauvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Guignabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Thuillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lih-Yun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"1","key":"3687_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","volume":"8","author":"S Bhattacharyya","year":"2012","unstructured":"Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2012;8(1):42\u201354.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"3687_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1(1):1\u201321.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3687_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jbspin.2014.10.010","volume":"82","author":"M Elhai","year":"2015","unstructured":"Elhai M, Avouac J, Kahan A, Allanore Y. Systemic sclerosis: recent insights. Joint Bone Spine. 2015;82(3):148\u201353.","journal-title":"Joint Bone Spine"},{"issue":"10","key":"3687_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Air\u00f2 P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3687_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2021","unstructured":"Volkmann ER, Fischer A. Update on morbidity and mortality in systemic sclerosis\u2013related interstitial lung disease. Journal of Scleroderma and Related Disorders. 2021;6(1):11\u201320.","journal-title":"Journal of Scleroderma and Related Disorders"},{"issue":"3","key":"3687_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. Journal of Scleroderma and Related Disorders. 2017;2(3):137\u201352.","journal-title":"Journal of Scleroderma and Related Disorders"},{"issue":"6","key":"3687_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/BOR.0000000000000735","volume":"32","author":"C Orvain","year":"2020","unstructured":"Orvain C, Assassi S, Avouac J, Allanore Y. Systemic sclerosis pathogenesis: contribution of recent advances in genetics. Curr Opin Rheumatol. 2020;32(6):505\u201314.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"3687_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","volume":"64","author":"ME Truchetet","year":"2023","unstructured":"Truchetet ME, Brembilla NC, Chizzolini C. Current concepts on the pathogenesis of systemic sclerosis. Clin Rev Allergy Immunol. 2023;64(3):262\u201383.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"3687_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly S, H\u00fcgle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatol Oxf Engl. 2012;51(9):1540\u20139.","journal-title":"Rheumatol Oxf Engl"},{"issue":"8","key":"3687_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1600-0625.2008.00828.x","volume":"18","author":"N Higashi-Kuwata","year":"2009","unstructured":"Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol. 2009;18(8):727\u20139.","journal-title":"Exp Dermatol"},{"issue":"1","key":"3687_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.humimm.2014.12.008","volume":"76","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Hou W, Xu K, Han D, Jiang C, Mou K, et al. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol. 2015;76(1):22\u20139.","journal-title":"Hum Immunol"},{"issue":"1","key":"3687_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08916934.2017.1416467","volume":"51","author":"RSG Gon\u00e7alves","year":"2018","unstructured":"Gon\u00e7alves RSG, Pereira MC, Dantas AT, de Almeida AR, Marques CDL, Rego MJBM, et al. IL-17 and related cytokines involved in systemic sclerosis: perspectives. Autoimmunity. 2018;51(1):1\u20139.","journal-title":"Autoimmunity"},{"key":"3687_CR13","doi-asserted-by":"crossref","unstructured":"Wei L, Abraham D, Ong V. The Yin and Yang of IL-17 in Systemic Sclerosis. Front Immunol . 2022;13. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2022.885609. Cited 29 Feb 2024.","DOI":"10.3389\/fimmu.2022.885609"},{"issue":"1","key":"3687_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.immuni.2006.05.012","volume":"25","author":"LO Atherly","year":"2006","unstructured":"Atherly LO, Lucas JA, Felices M, Yin CC, Reiner SL, Berg LJ. The tec family tyrosine kinases Itk and Rlk regulate the development of conventional CD8\u2009+\u2009T cells. Immunity. 2006;25(1):79\u201391.","journal-title":"Immunity"},{"issue":"2","key":"3687_CR15","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4049\/jimmunol.1302059","volume":"193","author":"AL Prince","year":"2014","unstructured":"Prince AL, Kraus Z, Carty SA, Ng C, Yin CC, Jordan MS, et al. Development of innate CD4\u2009+\u2009and CD8\u2009+\u2009T cells in Itk-deficient mice is regulated by distinct pathways. J Immunol. 2014;193(2):688\u201399.","journal-title":"J Immunol"},{"issue":"9","key":"3687_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107490","volume":"9","author":"A Deakin","year":"2014","unstructured":"Deakin A, Duddy G, Wilson S, Harrison S, Latcham J, Fulleylove M, et al. Characterisation of a K390R ITK kinase dead transgenic mouse\u2013implications for ITK as a therapeutic target. PLoS One. 2014;9(9):e107490.","journal-title":"PLoS One"},{"issue":"2","key":"3687_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/08830185.2012.668981","volume":"31","author":"A August","year":"2012","unstructured":"August A, Ragin MJ. Regulation of T-cell responses and disease by tec kinase Itk. Int Rev Immunol. 2012;31(2):155\u201365.","journal-title":"Int Rev Immunol"},{"issue":"1","key":"3687_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.immuni.2004.06.009","volume":"21","author":"AT Miller","year":"2004","unstructured":"Miller AT, Wilcox HM, Lai Z, Berg LJ. Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. Immunity. 2004;21(1):67\u201380.","journal-title":"Immunity"},{"issue":"10","key":"3687_CR19","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.4049\/jimmunol.170.10.5056","volume":"170","author":"C Mueller","year":"2003","unstructured":"Mueller C, August A. Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK. J Immunol. 2003;170(10):5056\u201363.","journal-title":"J Immunol"},{"issue":"6","key":"3687_CR20","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.4049\/jimmunol.180.6.3833","volume":"180","author":"N Sahu","year":"2008","unstructured":"Sahu N, Mueller C, Fischer A, August A. Differential sensitivity to Itk kinase signals for T helper 2 cytokine production and chemokine mediated migration. J Immunol. 2008;180(6):3833\u20138.","journal-title":"J Immunol"},{"key":"3687_CR21","doi-asserted-by":"crossref","unstructured":"Hsu LY, Rosenbaum JT, Verner E, Jones WB, Hill CM, Janc JW et al. Selective Inhibition of Interleukin-2 Inducible T Cell Kinase (ITK) Enhances Anti-Tumor Immunity in Association with Th1-skewing, Cytotoxic T cell Activation, and Reduced T Cell Exhaustion. bioRxiv; 2023. p. 2023.07.05.547822. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2023.07.05.547822v1. Cited 15 Mar 2024.","DOI":"10.1101\/2023.07.05.547822"},{"issue":"4","key":"3687_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jcp.41.4.467","volume":"41","author":"T Ashcroft","year":"1988","unstructured":"Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41(4):467\u201370.","journal-title":"J Clin Pathol"},{"issue":"8","key":"3687_CR23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/art.42111","volume":"74","author":"C Frantz","year":"2022","unstructured":"Frantz C, Cauvet A, Durand A, Gonzalez V, Pierre R, Do Cruzeiro M, et al. Driving role of interleukin-2-related regulatory CD4\u2009+\u2009T cell deficiency in the development of lung fibrosis and vascular remodeling in a mouse model of systemic sclerosis. Arthritis Rheumatol. 2022;74(8):1387\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3687_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/art.42677","volume":"76","author":"J Avouac","year":"2024","unstructured":"Avouac J, Cauvet A, Orvain C, Boulch M, Tilotta F, Tu L, et al. Effects of B cell depletion by CD19-targeted chimeric antigen receptor T cells in a murine model of systemic sclerosis. Arthritis Rheumatol. 2024;76(2):268\u201378.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"3687_CR25","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897\u2013905.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3687_CR26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/art.23406","volume":"58","author":"F Boin","year":"2008","unstructured":"Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum. 2008;58(4):1165\u201374.","journal-title":"Arthritis Rheum"},{"key":"3687_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156534","volume":"176","author":"N Seki","year":"2024","unstructured":"Seki N, Tsujimoto H, Tanemura S, Ishigaki S, Takei H, Sugahara K, et al. Th17\/IL-17A axis is critical for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc): SSc patients with high levels of serum IL-17A exhibit reduced lung functions and increased prevalence of PAH. Cytokine. 2024;176:156534.","journal-title":"Cytokine"},{"issue":"9","key":"3687_CR28","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/rheumatology\/keae190","volume":"63","author":"TI Papadimitriou","year":"2024","unstructured":"Papadimitriou TI, Lemmers JMJ, van Caam APM, Vos JL, Vitters EL, Stinissen L, et al. Systemic sclerosis-associated pulmonary arterial hypertension is characterized by a distinct peripheral T helper cell profile. Rheumatology. 2024;63(9):2525\u201334.","journal-title":"Rheumatology"},{"issue":"1","key":"3687_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03143-2","volume":"25","author":"A Cauvet","year":"2023","unstructured":"Cauvet A, Decellas A, Guignabert C, Rongvaux-Ga\u00efda D, Thuillet R, Ottaviani M, et al. Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis. Arthritis Res Ther. 2023;25(1):167.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3687_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1694-9","volume":"20","author":"G Boleto","year":"2018","unstructured":"Boleto G, Guignabert C, Pezet S, Cauvet A, Sadoine J, Tu L, et al. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Res Ther. 2018;20(1):197.","journal-title":"Arthritis Res Ther"},{"issue":"27","key":"3687_CR31","doi-asserted-by":"publisher","first-page":"E3901","DOI":"10.1073\/pnas.1523512113","volume":"113","author":"M Elhai","year":"2016","unstructured":"Elhai M, Avouac J, Hoffmann-Vold AM, Ruzehaji N, Amiar O, Ruiz B, et al. OX40L blockade protects against inflammation-driven fibrosis. Proc Natl Acad Sci U S A. 2016;113(27):E3901-3910.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"3687_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154631","volume":"11","author":"S Ebata","year":"2022","unstructured":"Ebata S, Yoshizaki-Ogawa A, Sato S, Yoshizaki A. New era in systemic sclerosis treatment: recently approved therapeutics. J Clin Med. 2022;11(15):4631.","journal-title":"J Clin Med"},{"key":"3687_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.biopha.2018.03.145","volume":"102","author":"L Yan","year":"2018","unstructured":"Yan L, Song F, Li H, Li Y, Li J, He QY, et al. Submicron emulsion of cinnamaldehyde ameliorates bleomycin-induced idiopathic pulmonary fibrosis via inhibition of inflammation, oxidative stress and epithelial-mesenchymal transition. Biomed Pharmacother. 2018;102:765\u201371.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3687_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-023-02349-z","volume":"23","author":"A Gul","year":"2023","unstructured":"Gul A, Yang F, Xie C, Du W, Mohammadtursun N, Wang B, et al. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin. BMC Pulm Med. 2023;23(1):91.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"3687_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.vph.2012.12.001","volume":"58","author":"B Maurer","year":"2013","unstructured":"Maurer B, Distler JHW, Distler O. The Fra-2 transgenic mouse model of systemic sclerosis. Vascul Pharmacol. 2013;58(3):194\u2013201.","journal-title":"Vascul Pharmacol"},{"issue":"8","key":"3687_CR36","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41409-023-02001-8","volume":"58","author":"S Palaniyandi","year":"2023","unstructured":"Palaniyandi S, Strattan E, Kumari R, Mysinger M, Hakim N, Kesler MV, et al. Combinatorial inhibition of tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease. Bone Marrow Transplant. 2023;58(8):924\u201335.","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"3687_CR37","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539\u201349.","journal-title":"Blood"},{"key":"3687_CR38","doi-asserted-by":"crossref","unstructured":"Hsu LY, Rosenbaum JT, Lindner S, Allanore Y, Cauvet A, Pawar RD, Soquelitinib et al. A Selective Inhibitor of Interleukin-2-Inducible T Cell Kinase (ITK), is Active in Several Murine Models of T Cell-Mediated Inflammatory Disease. bioRxiv; 2023. p. 2023.10.27.564296. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2023.10.27.564296v1. Cited 19 Sep 2025.","DOI":"10.1101\/2023.10.27.564296"},{"key":"3687_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.109408","volume":"64","author":"A Birnhuber","year":"2019","unstructured":"Birnhuber A, Biasin V, Schnoegl D, Marsh LM, Kwapiszewska G. Transcription factor Fra-2 and its emerging role in matrix deposition, proliferation and inflammation in chronic lung diseases. Cell Signal. 2019;64:109408.","journal-title":"Cell Signal"},{"issue":"4","key":"3687_CR40","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1164\/ajrccm\/144.4.892","volume":"144","author":"RM Cherniack","year":"1991","unstructured":"Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron J, Ackerson L, et al. Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. The BAL cooperative group steering committee. Am Rev Respir Dis. 1991;144(4):892\u2013900.","journal-title":"Am Rev Respir Dis"},{"issue":"12","key":"3687_CR41","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","volume":"75","author":"M Ponsoye","year":"2016","unstructured":"Ponsoye M, Frantz C, Ruzehaji N, Nicco C, Elhai M, Ruiz B, et al. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann Rheum Dis. 2016;75(12):2142\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3687_CR42","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","volume":"76","author":"J Avouac","year":"2017","unstructured":"Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, et al. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017;76(11):1931\u201340.","journal-title":"Ann Rheum Dis"},{"key":"3687_CR43","doi-asserted-by":"crossref","unstructured":"Chaumais MC, Djessas MRA, Thuillet R, Cumont A, Tu L, Hebert G, et al. Additive protective effects of sacubitril\/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovasc Res. 2021;117(5):1391\u2013401.","DOI":"10.1093\/cvr\/cvaa200"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03687-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:27:35Z","timestamp":1766500055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03687-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3687"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03687-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments using the bleomycin-induced lung fibrosis model were conducted in accordance with the Institutional Animal Care and Use Committee guidelines and the animal welfare regulations of the U.S. federal and state regulations. The study was performed at Aragen, California, under protocol AUP# 20-0723-MR-1:\n                      Exploratory Study: Evaluation of Prophylactic or Therapeutic Efficacy of Test Compounds in Bleomycin-Induced Lung Fibrosis in Mice\n                      .Experiments using the Fra-2 model were conducted in compliance with EU legislation for the protection of animals used for scientific purposes (Directive 2010\/63\/EU) and were approved by the relevant ethics committee and the French Ministry of Research (APAFIS#23366-2019070110126750v5).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.B. received an honorarium from Boehringer for conference attendance.Y.A. received consulting honoraria from AstraZeneca, Boehringer, AbbVie, GSK, Novartis, Topadur, Prometheus, Galderma, Janssen, and Medsenic for work related to the management and treatment of systemic sclerosis.J.T.R. is a shareholder in Corvus Pharmaceuticals and was employed by the company at the time this work was conducted.L.Y.H. is an employee of Corvus Pharmaceuticals and holds stock and stock options in the company.R.A.M. is an employee of Corvus Pharmaceuticals and holds stock and stock options in the company.Over the past three years, C.G. has received research grants from MSD, Corteria, Structure Therapeutics (formerly ShouTi), Gossamer Bio, and Diagonal Therapeutics, all unrelated to the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}